Research contributes to revised decision on availability of Alzheimer's drugs
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced today (18th January 2011).
A previous appraisal by NICE of these drugs in 2004 approved the use of donepezil, galantamine and rivastigmine for people with moderate Alzheimer's disease, while the use of memantine was restricted to clinical trials.
As part of its ongoing review of its previous decisions, NICE requested a review of new evidence which was carried out by PenTAG, which is independent of NICE.
The evidence showed that little had changed and that all the drugs had some effect on delaying symptom progression in Alzheimer's. PenTAG also noted the uncertainty surrounding the estimates used in the previous economic model and hence its results. A new economic model developed by PenTAG and which was calibrated differently to the model used in the previous assessment, showed the drugs to be cost-effective, although some uncertainty remains.
As a consequence, the report from PenTAG was a key piece of evidence that has informed the decision by NICE's appraisal committee to extend the availability of donepezil, galantamine and rivastigmine to people with mild Alzheimer's disease, and memantine to those with severe forms of the disease.
Professor Chris Hyde from PenTAG commented: "Alzheimer's disease and dementia are a growing problem for the UK. The Alzheimer's Society estimates that there are 750,000 people with dementia in the UK today, and that this figure will grow to over one million by 2025. The costs associated with the disease are huge, with over 60,000 deaths attributed to dementia and a national financial cost to the country of £20 billion. Our work for NICE allows a rigorous and independent re-assessment of the balance of research evidence for additional patient benefits against the extra costs to the NHS of providing different treatments."
Andrew Gould | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...